Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Abierto

2.45 -0.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.43

Máximo

2.54

Métricas clave
By Trading Economics
Ingresos	663K -7M
Ventas	426K 2.6M
P/B Media del Sector	6.816 56.597
BPA	-0.07
Margen de beneficios	-269.254
Empleados	75
EBITDA	665K -7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+101.61% upside

Dividendos
By Acuity
Próximas Ganancias	9 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	20M 245M
Apertura anterior	2.86
Cierre anterior	2.45

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2026, 23:56 UTC

Revolve Group Inc shares are higher in after-market hours, maintaining an upward trend since Wednesday's close, despite being below the 20-day moving average.

9 sept 2026, 23:56 UTC

Correlated Moves

Procore Technologies Inc shares are higher in after-market hours, recovering from an initial decline. The stock remains below its 20-day moving average.

9 sept 2026, 23:56 UTC

BlackLine Inc. shares rose in after-market trading, recovering from an initial dip. The stock remains below its 20-day moving average amid broader market challenges.

9 sept 2026, 23:56 UTC

MetLife Inc shares are lower in after-market hours amid heightened market anxiety over geopolitical tensions and upcoming economic data releases.

9 sept 2026, 23:56 UTC

Warner Bros Discovery Inc. shares are higher in after-market trading, despite earlier fluctuations and amid broader market anxiety over geopolitical tensions and economic data.

9 sept 2026, 23:56 UTC

JinkoSolar Holding Co Ltd shares are lower in after-market hours, continuing a decline amid market anxiety over geopolitical tensions and upcoming economic data releases.

9 sept 2026, 23:56 UTC

No specific news was identified for Solaredge Technologies. Shares traded roughly flat in after-market hours, remaining near the upper end of their one-month range.

9 sept 2026, 23:53 UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

9 sept 2026, 23:52 UTC

ACI Worldwide shares declined in after-market trading, continuing a downward trend from regular trading and reflecting ongoing selling pressure amid broader market conditions.

9 sept 2026, 23:52 UTC

The NZD/CHF is trading lower during Wednesday's session, reflecting routine movement near its one-month trading range's lower end. No specific news was identified.

9 sept 2026, 23:51 UTC

Correlated Moves

Ares Management shares are higher in after-market trading, reflecting positive market conditions and aligning with upward trends in correlated assets like Brookfield Corp.

9 sept 2026, 23:51 UTC

Correlated Moves

ACNB Corp shares are lower in after-market hours, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

9 sept 2026, 23:51 UTC

News

Toll Brothers Inc. shares are lower in after-market trading, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

9 sept 2026, 23:51 UTC

Lamb Weston Holdings Inc shares are higher in after-market hours, reflecting an increase since Wednesday's close, despite recent underperformance and no specific news identified.

9 sept 2026, 23:51 UTC

ManpowerGroup Inc. shares are lower in after-market hours, continuing a decline below the 20-day moving average amid broader market weakness.

9 sept 2026, 23:51 UTC

MVB Financial Corp shares traded higher in after-market hours, reaching 0.42% above Wednesday's close and remaining above their 20-day moving average.

9 sept 2026, 23:51 UTC

Travelers Companies Inc shares are higher in after-market hours, reaching a peak return after an initial dip. No specific news was identified for this movement.

9 sept 2026, 23:51 UTC

Movado Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

9 sept 2026, 23:51 UTC

UK Housing Market Shows Signs of Stabilization with Slight Improvement in House Price Balance, Amidst Cautious Optimism and Ongoing Economic Challenges

9 sept 2026, 23:51 UTC

Existing Home Sales Expected to Decline Amid High Mortgage Rates and Decreased Buyer Demand

9 sept 2026, 23:51 UTC

US Existing Home Sales Data for August 2026 Expected at 3.98 Million Amid Rising Inventory and High Mortgage Rates.

9 sept 2026, 23:51 UTC

Brazil's Central Bank Faces Critical Interest Rate Decision Amid Inflation Concerns and Economic Resilience on September 16, 2026.

9 sept 2026, 23:51 UTC

Chubb Limited shares are lower in after-market hours, continuing a trend of declining prices. The stock is below its 20-day moving average.

9 sept 2026, 23:51 UTC

Amerisafe Inc shares are higher after market hours, despite a slight decline earlier. The stock remains below its 20-day moving average.

9 sept 2026, 23:51 UTC

Correlated Moves

Carlyle Group Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions amid broader positive market dynamics despite rising crude oil prices.

9 sept 2026, 23:51 UTC

Patrick Industries Inc. shares declined after market hours, continuing a trend of lower closes. The stock remains significantly below the 20-day moving average.

9 sept 2026, 23:51 UTC

News

Lakeland Industries reported a fiscal Q2 net loss of $4.9 million and lower-than-expected sales, leading shares to decline in after-market trading.

9 sept 2026, 23:51 UTC

News

Limoneira Co reported third-quarter results that missed expectations, with revenues falling to $43.8 million and shares trading lower in after-market hours.

9 sept 2026, 23:51 UTC

Correlated Moves

EUR/CHF is trading higher, recovering from earlier lows and reflecting unusual intraday activity near the upper end of its one-month range.

9 sept 2026, 23:51 UTC

GBP/CHF is trading higher during Wednesday's session, recovering from an early dip and settling near the upper end of its one-month trading range.

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

101.61% repunte

Estimación a 12 Meses

Media 5 USD 101.61%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.